drugset / Trial / NCT00486434

Efficacy and Safety of Oral Salmon Calcitonin in Patients With Knee Osteoarthritis

NCT00486434

Phase 3 Completed 1176 enrolled Nordic Bioscience A/S Novartis · collab
RandomizedParallel-groupDouble-blindTreatment

Summary

The purpose of this Phase III study is to evaluate the efficacy and safety of oral salmon calcitonin in the treatment of patients with osteoarthritis of the knee.

Timeline

Start
2007-05
Primary completion
2010-09
Completion
2010-09

Publications

Drugs

EvaluationDrugModalityDoseRoute
Comparator salmon calcitonin Unknown 0.8 mg Oral

Indications